Cladribine (Mavenclad) gets European licence for highly active relapsing MS
Source MS Trust: The European Commission (EC) has granted marketing authorization for cladribine (Mavenclad)for the treatment of adults with highly active relapsing multiple sclerosis. This follows a recommendation from the European Medicines Agency in June that a licence should be granted.
Cladribine (Mavenclad) gets European licence for highly active relapsing MS Read More »









